...its Asegua Therapeutics LLC subsidiary in 2018 to offer generic versions of Epclusa and Harvonisofosbuvir/ledipasvir... ...with a wholesale acquisition cost (WAC) of $74,760 for branded Epclusa and $94,500 for branded Harvoni...
...Sciences Inc. (NASDAQ:GILD) announced in September authorized generics for HCV drugs Epclusa sofosbuvir/velpatasvir and Harvonisofosbuvir/ledipasvir...
...generics and biosimilars. Sales of some Gilead Sciences Inc. (NASDAQ:GILD) antiviral products, such as Harvonisofosbuvir/ledipasvir... ...NYSE:JNJ) Odefsey emtricitabine/ rilpivirine/ tenofovir alafenamide $1,106.0 $1,150.0 $1,533.3 39% Gilead Sciences Inc. (NASDAQ:GILD) Harvonisofosbuvir/ledipasvir... .../ velpatasvir HCV infection China Australia, Canada, EU, U.S. in 2016 Gilead Sciences Inc. (NASDAQ:GILD) Harvoni...
...the last two years due to declining revenues from HCV blockbusters Sovaldi sofosbuvir and Harvonisofosbuvir/ledipasvir... ...market access. In 2015, about three months after the launch of its follow-on drug Harvonisofosbuvir/ledipasvir...
...new approvals for three drugs marketed in the U.S. and EU: Descovy emtricitabine/tenofovir alafenamide and Harvoni... ...HIV-1 infection in patients aged 12 and older in combination with other antiretroviral agents, while Harvoni... ...emtricitabine/tenofovir alafenamide (Generic), F/TAF (Informal), Descovy (Other)
Harvoni (Brand), GS-7977/GS-5885, sofosbuvir/ledipasvir (Generic), sofosbuvir (GS-7977)/ledipasvir (GS-5885) (Informal), ledipasvir (GS-5885)/sofosbuvir (GS-7977) (Informal), Harvoni...